Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, has been hailed as a revolutionary tool in ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Group Dinner Meeting to be held in New York on February 5 at 6 pm hosted by Truist. Maximize Your Portfolio with Data Driven Insights:Leverage ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...